Premium
In an otherwise lean month of deal-making, domestic private equity major ChrysCapital’s decision to reinvest in Mankind Pharma, barely three years after exiting its investment in the firm with multi-bagger returns, proved to be a booster dose for the Indian healthcare sector.It also says a lot about how the homegrown ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
